← Back to Search

Semaglutide for Type 2 Diabetes

Phase 2
Waitlist Available
Research Sponsored by Novo Nordisk A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (week 0) to end of study (week 49)

Summary

This trial tests semaglutide in different doses to see how well it controls blood sugar and weight in people with type 2 diabetes who are overweight and taking metformin. The medicine is given as an injection under the skin. Semaglutide has been studied extensively for its effectiveness in controlling blood sugar and weight in type 2 diabetes, and it is available in both injectable and oral forms.

Eligible Conditions
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (week 0) to end of study (week 49)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (week 0) to end of study (week 49) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Glycosylated Haemoglobin (HbA1c)
Secondary study objectives
Change in Body Weight
Number of Treatment-emergent Adverse Events (TEAEs)
Number of Treatment-emergent Severe Hypoglycaemic Episodes

Side effects data

From 2020 Phase 4 trial • 104 Patients • NCT04189848
21%
Nausea
12%
Decreased Appetite
100%
80%
60%
40%
20%
0%
Study treatment Arm
Overall Study

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: Semaglutide 8 mgExperimental Treatment1 Intervention
Participants will receive once-weekly semaglutide 8 mg s.c. injection.
Group II: Semaglutide 2 mgExperimental Treatment1 Intervention
Participants will receive once-weekly semaglutide 2 mg subcutaneous (s.c.) injection.
Group III: Semaglutide 16 mgExperimental Treatment1 Intervention
Participants will receive once-weekly semaglutide 16 mg s.c. injection.
Group IV: Semaglutide placebo 2 mgPlacebo Group1 Intervention
Participants will receive once-weekly semaglutide placebo 2 mg s.c. injection.
Group V: Semaglutide placebo 8 mgPlacebo Group1 Intervention
Participants will receive once-weekly semaglutide placebo 8 mg s.c. injection.
Group VI: Semaglutide placebo 16 mgPlacebo Group1 Intervention
Participants will receive once-weekly semaglutide placebo 16 mg s.c. injection.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Semaglutide
2021
Completed Phase 4
~5160

Find a Location

Who is running the clinical trial?

Novo Nordisk A/SLead Sponsor
1,549 Previous Clinical Trials
2,443,787 Total Patients Enrolled
Clinical Transparency (dept. 2834)Study DirectorNovo Nordisk A/S
129 Previous Clinical Trials
152,053 Total Patients Enrolled

Media Library

Placebo Clinical Trial Eligibility Overview. Trial Name: NCT05486065 — Phase 2
Type 2 Diabetes Research Study Groups: Semaglutide 8 mg, Semaglutide 2 mg, Semaglutide placebo 2 mg, Semaglutide placebo 8 mg, Semaglutide 16 mg, Semaglutide placebo 16 mg
Type 2 Diabetes Clinical Trial 2023: Placebo Highlights & Side Effects. Trial Name: NCT05486065 — Phase 2
Placebo 2023 Treatment Timeline for Medical Study. Trial Name: NCT05486065 — Phase 2
Type 2 Diabetes Patient Testimony for trial: Trial Name: NCT05486065 — Phase 2
~77 spots leftby Oct 2025